Jay B. Fell

发表

Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.

J. Blake, J. Christensen, B. Brandhuber, 2018, ACS medicinal chemistry letters.

HPLC/NMR in Combinatorial Chemistry

M. Jarosinski, M. Shapiro, J. Wareing, 1998 .

Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors.

J. E. Robinson, J. Blake, S. Le Pogam, 2009, Bioorganic & medicinal chemistry letters.

Progression of Organic Reactions on Resin Supports Monitored by Single Bead FTIR Microspectroscopy.

B. Yan, G. Kumaravel, Jay B. Fell, 1996, The Journal of organic chemistry.

Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer

J. Blake, J. Christensen, G. Vigers, 2020 .

A Mild and Efficient Preparation of Carbodiimides

G. Coppola, Jay B. Fell, 1995 .

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.

J. Blake, J. Christensen, J. Lawson, 2021, Journal of medicinal chemistry.

The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients.

J. Fernandez-Banet, A. Pavlícek, J. Christensen, 2019, Cancer discovery.

Squalene synthase inhibitors: isosteric replacements of the farnesyl chain of benzyl farnesyl amine

T. Scallen, R. Damon, J. Brinkman, 1996 .

Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides.

April Wong, J. E. Robinson, Jim Li, 2009, Bioorganic & medicinal chemistry letters.